2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of …

E Arbelo, A Protonotarios, JR Gimeno… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …

TA McDonagh, M Metra, M Adamo… - European heart …, 2021 - academic.oup.com
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

P Garcia-Pavia, C Rapezzi, Y Adler, M Arad… - European heart …, 2021 - academic.oup.com
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology W orking G roup on M yocardial and P ericardial D …

P Garcia‐Pavia, C Rapezzi, Y Adler… - European journal of …, 2021 - Wiley Online Library
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Transthyretin cardiac amyloidosis

A Porcari, M Fontana, JD Gillmore - Cardiovascular Research, 2022 - academic.oup.com
Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart
failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the …

Prevalence, characteristics and outcomes of older patients with hereditary versus wild‐type transthyretin amyloid cardiomyopathy

A Porcari, Y Razvi, A Masi, R Patel… - European journal of …, 2023 - Wiley Online Library
Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is often assumed to be associated
with wild‐type TTR genotype (ATTRwt) in elderly patients (aged≥ 70), some of whom are …

Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey

M Merlo, L Pagura, A Porcari, M Cameli… - European Journal of …, 2022 - Wiley Online Library
Aim To investigate the prevalence of amyloid cardiomyopathy (AC) and the diagnostic
accuracy of echocardiographic red flags of AC among consecutive adult patients …

A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction

DR Davies, MM Redfield, CG Scott… - JAMA …, 2022 - jamanetwork.com
Importance Transthyretin amyloid cardiomyopathy (ATTR-CM) is a form of heart failure (HF)
with preserved ejection fraction (HFpEF). Technetium Tc 99m pyrophosphate scintigraphy …

Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review

C Rapezzi, A Aimo, M Serenelli, A Barison… - Journal of the American …, 2022 - jacc.org
Over the last year, 5 national or international scientific societies have issued documents
regarding cardiac amyloidosis (CA) to highlight the emerging clinical science, raise …

Cardiac amyloidosis and aortic stenosis: a state-of-the-art review

V Jaiswal, V Agrawal, Y Khulbe, M Hanif… - … Heart Journal Open, 2023 - academic.oup.com
Cardiac amyloidosis is caused by the extracellular deposition of amyloid fibrils in the heart,
involving not only the myocardium but also any cardiovascular structure. Indeed, this …